In focus · trending topic

Orphan Designation

2 stories · following the connections

Cascadian Therapeutics Announces FDA Orphan Drug Designation Granted to Tucatinib for the Treatment of HER2+ Metastatic Colorectal Cancer

By Nasdaq OMXSep 27, 2017, 11:00 AM UTC

Cascadian Therapeutics’ Lead Candidate, Tucatinib, Receives Orphan Drug Designation from FDA for Treatment of Breast Cancer Patients with Brain Metastases

By Nasdaq OMXJun 8, 2017, 12:01 PM UTC